BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36083295)

  • 1. Perspectives of topical formulations for melasma.
    de Freitas ACP; Rigon RB; Bagatin E; Leonardi GR
    Int J Dermatol; 2023 Feb; 62(2):260-268. PubMed ID: 36083295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of melasma with topical agents, peels and lasers: an evidence-based review.
    Rivas S; Pandya AG
    Am J Clin Dermatol; 2013 Oct; 14(5):359-76. PubMed ID: 23881551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical therapies for melasma.
    Mahajan VK; Patil A; Blicharz L; Kassir M; Konnikov N; Gold MH; Goldman MP; Galadari H; Goldust M
    J Cosmet Dermatol; 2022 Sep; 21(9):3707-3728. PubMed ID: 35854432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Efficacy Of 35% Glycolic Acid Peel vs. Jessner Peel as an Adjuvant to Topical Triple Combination (2% Hydroquinone, 0.025% Tretinoin, 0.01% Fluocinolone Acetonide) Therapy in Melasma Females Cases.
    Modi A; Parmar S; Marfatiya Y
    J Cosmet Sci; 2021; 72(4):418-431. PubMed ID: 35262482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for the use of topical corticosteroids in melasma.
    Menter A
    J Drugs Dermatol; 2004; 3(2):169-74. PubMed ID: 15098972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma.
    Sahu PJ; Singh AL; Kulkarni S; Madke B; Saoji V; Jawade S
    J Cosmet Dermatol; 2020 Jun; 19(6):1456-1462. PubMed ID: 32346962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Tranexemic Acid With Triple Combination Cream (Flucinolone+Hydroquinone+Tretinoin) Versus Triple Combination Cream Alone In Treatment Of Melasma.
    Basit A; Rahman A; Uddin R
    J Ayub Med Coll Abbottabad; 2021; 33(2):293-298. PubMed ID: 34137548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.
    Taylor SC; Torok H; Jones T; Lowe N; Rich P; Tschen E; Menter A; Baumann L; Wieder JJ; Jarratt MM; Pariser D; Martin D; Weiss J; Shavin J; Ramirez N
    Cutis; 2003 Jul; 72(1):67-72. PubMed ID: 12889718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of cysteamine and methimazole in treating melasma: A comparative narrative review.
    Niazi S; Gheisari M; Moravvej H; Doroodgar F; Niazi F
    J Cosmet Dermatol; 2022 Sep; 21(9):3867-3875. PubMed ID: 35751542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of retinoic acid in the treatment of melasma.
    Pathak MA; Fitzpatrick TB; Kraus EW
    J Am Acad Dermatol; 1986 Oct; 15(4 Pt 2):894-9. PubMed ID: 3534025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilizing combination therapy to optimize melasma outcomes.
    Rendon MI
    J Drugs Dermatol; 2004; 3(5 Suppl):S27-34. PubMed ID: 15552597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of hydroquinone-resistant melasma using topical methimazole.
    Malek J; Chedraoui A; Nikolic D; Barouti N; Ghosn S; Abbas O
    Dermatol Ther; 2013; 26(1):69-72. PubMed ID: 23384022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of topical retinoids in the treatment of pigmentary disorders: an evidence-based review.
    Kang HY; Valerio L; Bahadoran P; Ortonne JP
    Am J Clin Dermatol; 2009; 10(4):251-60. PubMed ID: 19489658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical metformin in the treatment of melasma: A preliminary clinical trial.
    Banavase Channakeshavaiah R; Andanooru Chandrappa NK
    J Cosmet Dermatol; 2020 May; 19(5):1161-1164. PubMed ID: 31502392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melasma in Latin America: options for therapy and treatment algorithm.
    Cestari T; Arellano I; Hexsel D; Ortonne JP;
    J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):760-72. PubMed ID: 19646135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of melasma: a review of clinical trials.
    Gupta AK; Gover MD; Nouri K; Taylor S
    J Am Acad Dermatol; 2006 Dec; 55(6):1048-65. PubMed ID: 17097400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Best practices in the treatment of melasma with a focus on patients with skin of color.
    Desai SR; Alexis AF; Elbuluk N; Grimes PE; Weiss J; Hamzavi IH; Taylor SC
    J Am Acad Dermatol; 2024 Feb; 90(2):269-279. PubMed ID: 37748556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream.
    Bhawan J; Grimes P; Pandya AG; Keady M; Byers HR; Guevara IL; Colón LE; Johnson LA; Gottschalk R
    Am J Dermatopathol; 2009 Dec; 31(8):794-8. PubMed ID: 19755910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream.
    Torok HM
    Am J Clin Dermatol; 2006; 7(4):223-30. PubMed ID: 16901182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions for melasma.
    Rajaratnam R; Halpern J; Salim A; Emmett C
    Cochrane Database Syst Rev; 2010 Jul; (7):CD003583. PubMed ID: 20614435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.